Figure 1.
MIR22HG was downregulated in prostate cancer. In GEPIA (A), GSE45016 (B), GSE6919 (C), GSE55945 (D), and TCGA (E) datasets MIR22HG was significantly downregulated in PCa samples. (*P < 0.05, ***P < 0.001.).
Citation: Hao Shen, Xiao-Dong Weng, Du Yang, Lei Wang, Xiu-Heng Liu. Long noncoding RNA MIR22HG is down-regulated in prostate cancer[J]. Mathematical Biosciences and Engineering, 2020, 17(2): 1776-1786. doi: 10.3934/mbe.2020093
| [1] | Yonghua Xue, Yiqin Ge . Construction of lncRNA regulatory networks reveal the key lncRNAs associated with Pituitary adenomas progression. Mathematical Biosciences and Engineering, 2020, 17(3): 2138-2149. doi: 10.3934/mbe.2020113 |
| [2] | Sijie Lu, Juan Xie, Yang Li, Bin Yu, Qin Ma, Bingqiang Liu . Identification of lncRNAs-gene interactions in transcription regulation based on co-expression analysis of RNA-seq data. Mathematical Biosciences and Engineering, 2019, 16(6): 7112-7125. doi: 10.3934/mbe.2019357 |
| [3] | Yue Hu, Xiaoqin Mei, Dong Tang . Long non-coding RNA XIST is down-regulated and correlated to better prognosis in ovarian cancer. Mathematical Biosciences and Engineering, 2020, 17(3): 2070-2081. doi: 10.3934/mbe.2020110 |
| [4] | Ziyu Wu, Sugui Wang, Qiang Li, Qingsong Zhao, Mingming Shao . Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma. Mathematical Biosciences and Engineering, 2020, 17(3): 2037-2047. doi: 10.3934/mbe.2020108 |
| [5] | Zhongwei Zhao, Xiaoxi Fan, Lili Yang, Jingjing Song, Shiji Fang, Jianfei Tu, Minjiang Chen, Liyun Zheng, Fazong Wu, Dengke Zhang, Xihui Ying, Jiansong Ji . The identification of a common different gene expression signature in patients with colorectal cancer. Mathematical Biosciences and Engineering, 2019, 16(4): 2942-2958. doi: 10.3934/mbe.2019145 |
| [6] | Xudan Ma, Qijun Zhang, Haihong Zhu, Kefeng Huang, Weina Pang, Qin Zhang . Establishment and analysis of the lncRNA-miRNA-mRNA network based on competitive endogenous RNA identifies functional genes in heart failure. Mathematical Biosciences and Engineering, 2021, 18(4): 4011-4026. doi: 10.3934/mbe.2021201 |
| [7] | Shuai Miao, Lijun Wang, Siyu Guan, Tianshu Gu, Hualing Wang, Wenfeng Shangguan, Weiding Wang, Yu Liu, Xue Liang . Integrated whole transcriptome analysis for the crucial regulators and functional pathways related to cardiac fibrosis in rats. Mathematical Biosciences and Engineering, 2023, 20(3): 5413-5429. doi: 10.3934/mbe.2023250 |
| [8] | Jinmiao Song, Shengwei Tian, Long Yu, Qimeng Yang, Qiguo Dai, Yuanxu Wang, Weidong Wu, Xiaodong Duan . RLF-LPI: An ensemble learning framework using sequence information for predicting lncRNA-protein interaction based on AE-ResLSTM and fuzzy decision. Mathematical Biosciences and Engineering, 2022, 19(5): 4749-4764. doi: 10.3934/mbe.2022222 |
| [9] | Qinyan shen, Jiang wang, Liangying zhao . To investigate the internal association between SARS-CoV-2 infections and cancer through bioinformatics. Mathematical Biosciences and Engineering, 2022, 19(11): 11172-11194. doi: 10.3934/mbe.2022521 |
| [10] | Yan Li, Yuzhang Zhu, Guiping Dai, Dongjuan Wu, Zhenzhen Gao, Lei Zhang, Yaohua Fan . Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma. Mathematical Biosciences and Engineering, 2020, 17(1): 910-927. doi: 10.3934/mbe.2020048 |
Long noncoding RNAs were a type of RNA transcripts longer than 200 nucleotides. Emerging evidence indicated lncRNAs acted as key regulators in cancer tumorigenesis. A series of lncRNAs, such as GAS5, HOTAIR, NEAT1, and XIST, were abnormally expressed in various types of human cancers [1,2,3,4,5,6,7]. LncRNAs could also be classified into tumor-suppressive and oncogenic genes by regulating gene expression through transcriptional and post-transcriptional regulation. Prostate cancer (PCa) is the one of the most common malignancy in males. Recent studies had also focused on exploring the roles of lncRNAs in the progression of PCa. For example, White et al. found that low PCAT-14 expression associates with poor outcomes in PCa [8]. Chinnaiyan et al. reported ARLNC1 (AR-regulated long noncoding RNA 1) promoted PCa growth in vitro and in vivo [9]. However, the functional roles of most lncRNAs in PCa remained to be further investigated.
MiRNA host genes (MHG), a special type of lncRNAs, were revealed to be involved in regulating many biological processes, such as cetuximab resistance, metastasis, and cell proliferation. For instance, MIR31HG promoted lung cancer proliferation [10]. MiR210HG induced Osteosarcoma cell invasion and metastasis by sponging miR-503 [11]. MIR22HG was identified as a tumor suppressor in recent studies. Cui et al. found MIR22HG inhibited endometrial carcinoma proliferation by suppressing miR-141-3p [12]. Zhang et al. found MIR22HG overexpression suppressed hepatocellular carcinoma cell proliferation [13]. However, the expression pattern and function roles of MIR22HG in PCa remained unknown.
In the present study, we explored whether MIR22HG could serve as a biomarker for TC by analyzing public TCGA and GEO datasets. Meanwhile, we performed co-expression, GO analysis, and KEGG analysis to reveal the functional roles of MIR22HG in PCa. We thought this study will provide a novel prognostic biomarker for PCa.
A series of microarray datasets, including GEPIA, GSE6919 [14,15], GSE55945 [16], and GSE45016 [17] were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo/). GSE6919 was contributed by Chandran and GSE55945 was contributed by Arredouani. GSE45016 was contributed by Satake which contains 10 frozen specimens from high-grade PCs with high PSA levels and a high Gleason score (GS). The TCGA dataset of PCa contains 52 normal samples and 492 tumor samples. The clinical information of MIR22HG was download from cBioPortal (http://www.cbioportal.org/).
MIR22HG co-expressed genes were analyzed. MIR22HG -gene pairs with the absolute value of the Pearson correlation coefficient ≥ 0.4 were selected as candidates. Cytoscape was used to present the network.
MAS3.0 system (http://mas.capitalbiotech.com/mas3/) was a whole data-mining and function annotation solution to extract & analyze biological molecules relationships. We used MAS3.0 system to present the GO and KEGG analysis.
This study was approved by the Research Ethics Committee of Renmin Hospital of Wuhan University. A total of 9 normal and 13 tumor samples were obtained from Renmin Hospital of Wuhan University. Written informed consent was obtained from the patients with PCa. All patients did not have any other treatment before surgery. LNCaP, WPMY-1, PC-3 and C4-2B cells were obtained from Cell Bank of Chinese Academy of Sciences (Shanghai, China) and cultured in 1640-media supplemented with 10% FBS (Gibco, USA).
Total RNAs of samples and cell lines were extracted using TransZol Up Plus RNA Kit (TransGenBioTech, China). Reverse transcript PCR was carried out using PrimeScrip RT reagent Kit (TaKaRA, China). qRT-PCR was carried out using SuperRealPreMix Plus (TIANGEN, China) on Roche LightCycler 480. β-actin was selected as a reference. The primers for MIR22HG: Forward, 5’- CGGACGCAGTGATTTGCT-3’; reverse, 5’-GCTTTAGCTGGGTCAGGACA-3’. The 2-ΔΔCt method was used to calculated data.
Data were shown as a mean ± standard. The student’s t-test was used to compare between two groups of data. The Kaplan Meier plotter datasets were used to present the clinical significance of MIR22HG in PCa. The one-way analysis of variance (ANOVA) was used to compare between multiple groups. P < 0.05 was selected as significant.
To evaluate MIR22HG expression pattern in PCa, publicly available data from GEO and TCGA datasets were analyzed. As shown in Figure 1A-D, we first observed MIR22HG was significantly downregulated in PCa samples compared to normal samples by analyzing four publicly available gene expression datasets, including GEPIA, GSE45016, GSE6919, and GSE55945. Furthermore, we analyzed TCGA datasets and also found MIR22HG was down-regulated in PCa samples compared to normal prostate samples (Figure 1E).
Next, qRT-PCR assays were performed to validate MIR22HG expression in PCa cell lines and clinical samples. As shown in Figure 2, we found MIR22HG was down-regulated in PCa cell line, including LNCaP, PC-3, and C4-2B, compared with normal prostate cell line WPMY-1(Figure 2B, P < 0.05). These results were similar to the analysis based on Prensner et al. Dataset [18] (Figure 2A). Furthermore, we validate MIR22HG expression in 13 PCa tissues and 9 non-tumor samples. Our results showed that MIR22HG was significantly decreased in PCa tissues compared with non-tumor tissues (Figure 2C, P < 0.001).
Furthermore, we analyzed correlations between MIR22HG expression and clinicopathological features in prostate cancer specimens. Of note, our results showed that MIR22HG was significantly reduced in Gleason 6, Gleason 7, Gleason 8 and Gleason 9 + 10 PCa samples compared to the normal controls (Figure 3A, P < 0.001). Furthermore, we found MIR22HG was down-regulated in PCa with a Gleason score ≥ 8, compared with tumors with low Gleason score (≤ 7) (Figure 3A).
By analyzing its expression pattern based on T staging, we found that T2 (P < 0.001) and T3 + 4 (P < 0.001) PCa samples had lower expression of MIR22HG compared to the normal tissues (Figure 3B). Moreover, the expression level of MIR22HG was also decreased in pT3a, pT3b and T4 stages PCa as compared with pT2a, pT2b and pT2c stages PCa samples (P < 0.01) (Figure 3B).
In order to further investigate the clinical significance of MIR22HG in prostate cancer, we performed a Kaplan-Meier analysis. We found higher MIR22HG expression was significantly correlated with better disease-free survival time and overall survival time in prostate cancer (Figure 3C, D). These results suggested MIR22HG could act as a biomarker and prognostic target for prostate cancer.
By using the “guilt-by-association” approach, we predicted the potential roles of MIR22HG by analyzing its co-expressing mRNAs. We performed a co-expression analysis for MIR22HG in prostate cancer. The absolute value of the Pearson correlation coefficient ≥ 0.40 were selected as a cutoff to identified reliable MIR22HG-mRNA pairs.
Furthermore, we constructed MIR22HG-mediated PPI networks in prostate cancer by using its co-expressing mRNAs (combined score > 0.4) based on the STRING database [19,20]. As shown in Figure 4, this network contained 510 proteins and 3017 edges. Mcode plugin was performed to identify key genes (degree cut-off ≥ 2 and the nodes with edges ≥ 2-core) in this network. Key genes were labeled with green color (Figure 4).
We next performed GO analysis by using the DAVID system. GO analysis showed that MIR22HG co-expressed genes were significantly associated with inflammatory response, regulation of transcription, cellular response to tumor necrosis factor, neutrophil chemotaxis, cell-cell signaling, apoptotic process, immune response, activation of MAPK activity, cellular response to lipopolysaccharide, and positive regulation of cell migration (Figure 5A). Molecular function analysis showed MIR22HG was involved in regulating protein binding, transcription factor binding, cytokine activity, transcription factor activity, laminin binding (Figure 5B).
KEGG pathway analysis showed MIR22HG was involved in regulating TNF signaling pathway, Cytokine-cytokine receptor interaction, MAPK signaling pathway, NF-kappa B signaling pathway, Jak-STAT signaling pathway, p53 signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling pathway, Cytosolic DNA-sensing pathway, and PI3K-Akt signaling pathway (Figure 5C).
By analyzing TCGA, GEPIA, GSE6919, GSE55945, and GSE45016 datasets, our findings indicate that MIR22HG was downregulated in prostate cancer and correlated with clinic pathologic features and disease-free survival time of PCa. Bioinformatics analysis showed MIR22HG was significantly associated with regulating the inflammatory response, regulation of transcription, cellular response to tumor necrosis factor, neutrophil chemotaxis, cell-cell signaling, TNF signaling pathway, Cytokine-cytokine receptor interaction, MAPK signaling pathway, NF-kappa B signaling pathway, and Jak-STAT signaling pathway. These studies indicated MIR22HG might be a prognosis biomarker in PCa.
The initiation and progression of PCa is a complicated process involved in the dysregulation of various genes, such as AR, miRNAs, and transcription factors (TF). Moreover, multiple biomarkers, such as PSA glycoforms, TMPRSS2: ERG fusion gene, microRNAs, circulating tumor cells, lncRNAs, androgen receptor variants, and PTEN gene were revealed to be promising biomarkers for PCa prognosis [21]. Recent studies indicated lncRNAs also participated in regulating PCa tumorigenesis and could serve as novel biomarkers for PCa. A few lncRNAs were reported to be differently expressed in PCa, such as PCA3, TUG1 [22], HOTAIR, RNCR3 [23], and ARLNC1. For example, HOXD-AS1 regulated proliferation and chemo-resistance of castration-resistant PCa via recruiting WDR5 [24]. LncRNA PCA3 was more sensitive than traditional biomarker PSA in PCa diagnosis. In the present study, we focused on the roles of MIR22HG in PCa. First, we evaluated the expression pattern of MIR22HG in PCa by using GEPIA, GSE6919, GSE55945, GSE45016, and TCGA datasets. Then, we detected the endogenous expression level of MIR22HG in cell lines and in clinical samples excised from PCa patients by using a quantitative assessment of qRT-PCR. We found MIR22HG was significantly downregulated in human PCa tumors compared to non-cancerous prostate tissues. Moreover, we found the lower expression levels of MIR22HG were significantly related to higher Gleason and T stage. Kaplan-Meier analysis indicated higher MIR22HG expression was associated with longer disease-free survival time in PCa. These results suggested MIR22HG could serve as a novel biomarker for PCa.
Recent studies indicated miRNA host genes (MHG) played crucial roles in human cancers via regulating multiple biological processes. For example, Lu et al. found MIR100HG was up-regulated in cetuximab-resistant colorectal cancer and head and neck squamous cell cancer cells [25]. MIR100HG-derived miR-100 and miR-125b coordinately activated Wnt signaling to mediate cetuximab-resistant in cancer cells [25]. MIR22HG was a miRNA host gene and downregulated in lung cancer and hepatocellular carcinoma. MIR22HG was found to be involved in chemical stress response and hypoxia response. A recent study showed MIR22HG overexpression suppressed hepatocellular carcinoma cell proliferation [13]. However, the roles of MIR22HG in PCa remained largely unclear. In the present study, we constructed a MIR22HG mediated PPI network, which contained 510 proteins and 3017 edges. Bioinformatics analysis showed MIR22HG significantly associated with inflammatory response, regulation of transcription, cellular response to tumor necrosis factor, neutrophil chemotaxis, cell-cell signaling, TNF signaling pathway, Cytokine-cytokine receptor interaction, MAPK signaling pathway, NF-kappa B signaling pathway, and Jak-STAT signaling pathway.
In conclusion, this study for the first time showed MIR22HG was down-regulated in PCa. Furthermore, we observed the lower expression levels of MIR22HG were significantly related to higher Grade, T stage, N stage and shorter disease-free survival time in PCa. Bioinformatics analysis showed MIR22HG was associated with inflammatory response, regulation of transcription, and TNF signaling pathway. These results showed MIR22HG could serve as a novel biomarker for prostate cancer.
This study was supported by Application and Basic Research Project of Wuhan City (No. 2015060101010049), Wuhan Morning Light Plan of Youth Science and Technology (2017050304010281), Hubei Province Health and Family Planning Scientific Research Project (No. WJ2017M025, No. WJ2017Z005 and WJ2018H209), Natural Science Foundation of Hubei Province (No. 2016CFB114, 2017CFB181) and Research Project of Wuhan University (No. 2042017kf0097).
The authors declare that they have no competing interests, and all authors should confirm its accuracy.
| [1] | M. R. Pickard, M. Mourtada-Maarabouni, G. T. Williams, Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines, Biochim. Biophys. Acta Mol. Basis Dis., 1832 (2013), 1613-1623. |
| [2] | S. Cao, W. Liu, F. Li, W. Zhao, C. Qin, Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer, Int. J. Clin. Exp. Pathol., 7 (2014), 6776-6783. |
| [3] | X. H. Liu, M. Sun, F. Q. Nie, Y. B. Ge, E. B. Zhang, D. D. Yin, et al., Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer, Mol. Cancer, 13 (2014), 92. |
| [4] | X. H. Liu, Z. L. Liu, M. Sun, J. Liu, Z. X. Wang, W. De, The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer, BMC Cancer, 13 (2013), 464. |
| [5] | D. Chakravarty, A. Sboner, S. S. Nair, E. Giannopoulou, R. Li, S. Hennig, et al., The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer, Nat. Commun., 5 (2014), 5383. |
| [6] | C. Sun, S. Li, F. Zhang, Y. Xi, L. Wang, Y. Bi, et al., Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway, Oncotarget, 7 (2016), 51784-51814. |
| [7] | J. Fang, C. C. Sun, C. Gong, Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression, Biochem. Biophys. Res. Commun., 478 (2016), 811-817. |
| [8] | N. M. White, S. G. Zhao, J. Zhang, E. B. Rozycki, H. X. Dang, S. D. Mcfadden, et al., Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer, Eur. Urol., 71 (2017), 257-266. |
| [9] | Y. Zhang, S. Pitchiaya, M. Cieslik, Y. S. Niknafs, J. C. Y. Tien, Y. Hosono, et al., Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression, Nat. Genet., 50 (2018), 814-824. |
| [10] | J. Qin, H. Ning, Y. Zhou, Y. Hu, L. Yang, R. Huang, LncRNA MIR31HG overexpression serves as poor prognostic biomarker and promotes cells proliferation in lung adenocarcinoma, Biomed. Pharmacother., 99 (2018), 363-368. |
| [11] | J. Li, Q. M. Wu, X. Q. Wang, C. Q. Zhang, Long Noncoding RNA miR210HG Sponges miR-503 to Facilitate Osteosarcoma Cell Invasion and Metastasis, DNA Cell Biol., 36 (2017), 1117-1125. |
| [12] | Z. Cui, X. An, J. Li, Q. Liu, W. Liu, LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation, Biomed. Pharmacother., 104 (2018), 223-228. |
| [13] | D. Y. Zhang, X. J. Zou, C. H. Cao, T. Zhang, L. Lei, X. L. Qi, et al., Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma, Theranostics, 8 (2018), 3751-3765. |
| [14] | U. R. Chandran, C. Ma, R. Dhir, M. Bisceglia, M. Lyons-Weiler, W. Liang, et al., Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process, BMC Cancer, 7 (2007), 64. |
| [15] | Y. P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, et al., Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy, J. Clin. Oncol., 22 (2004), 2790-2799. |
| [16] | M. S. Arredouani, B. Lu, M. Bhasin, M. Eljanne, W. Yue, J. M. Mosquera, et al., Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer, Clin. Cancer Res., 15 (2009), 5794-5802. |
| [17] | H. Satake, K. Tamura, M. Furihata, T. Anchi, H. Sakoda, C. Kawada, et al., The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer, Oncol. Rep., 23 (2010), 11-16. |
| [18] | J. R. Prensner, W. Chen, M. K. Iyer, Q. Cao, T. Ma, S. Han, et al., PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer, Cancer Res., 74 (2014), 1651-1660. |
| [19] | J. H. Li, S. Liu, H. Zhou, L. H. Qu, J. H. Yang, starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data, Nucleic Acids Res., 42 (2014), D92-D97. |
| [20] | J. H. Yang, J. H. Li, P. Shao, H. Zhou, Y. Q. Chen, L. H. Qu, starBase: A database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data, Nucleic Acids Res., 39 (2011), D202-D209. |
| [21] | X. Filella, E. Fernandez-Galan, R. F. Bonifacio, L. Foj, Emerging biomarkers in the diagnosis of prostate cancer, Pharmgenomics Pers. Med., 11 (2018), 83-94. |
| [22] | B. Yang, X. Tang, Z. Wang, D. Sun, X. Wei, Y. Ding, TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a, Biosci. Rep., 38 (2018). |
| [23] | A. Matjasic, M. Tajnik, E. Bostjancic, M. Popovic, B. Matos, D. Glavac, Identifying novel glioma-associated noncoding RNAs by their expression profiles, Int. J. Genomics, 2017 (2017), 2312318. |
| [24] | P. Gu, X. Chen, R. Xie, J. Han, W. Xie, B. Wang, et al., lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5, Mol. Ther., 25 (2017), 1959-1973. |
| [25] | Y. Lu, X. Zhao, Q. Liu, C. Li, R. Graves-Deal, Z. Cao, et al., lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling, Nat. Med., 23 (2017), 1331-1341. |
| 1. | Elena A. Pudova, George S. Krasnov, Anastasiya A. Kobelyatskaya, Maria V. Savvateeva, Maria S. Fedorova, Vladislav S. Pavlov, Kirill M. Nyushko, Andrey D. Kaprin, Boris Y. Alekseev, Dmitry Y. Trofimov, Gennady T. Sukhikh, Anastasiya V. Snezhkina, Anna V. Kudryavtseva, Gene Expression Changes and Associated Pathways Involved in the Progression of Prostate Cancer Advanced Stages, 2021, 11, 1664-8021, 10.3389/fgene.2020.613162 | |
| 2. | Salman Khan, Mohammad Masood, Harshita Gaur, Shaniya Ahmad, Mansoor Ali Syed, Long non-coding RNA: An immune cells perspective, 2021, 271, 00243205, 119152, 10.1016/j.lfs.2021.119152 | |
| 3. | Wei Zhang, Chunmei Shi, Qian Xu, Xinfeng Chen, Hua Zhu, Bing Zheng, Long non-coding RNA MIR22HG suppresses cell proliferation and promotes apoptosis in prostate cancer cells by sponging microRNA-9-3p, 2022, 13, 2165-5979, 13108, 10.1080/21655979.2022.2079244 | |
| 4. | Mohammad Taheri, Elham Badrlou, Bashdar Mahmud Hussen, Amir Hossein Kashi, Soudeh Ghafouri-Fard, Aria Baniahmad, Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer, 2023, 13, 2234-943X, 10.3389/fonc.2023.1123101 | |
| 5. | Jitendra Gupta, Waleed K. Abdulsahib, Abduladheem Turki Jalil, Doaa Saadi Kareem, Zafar Aminov, Fahad Alsaikhan, Ramirez-CoronelAndrés Alexis Ramírez-Coronel, Pushpamala Ramaiah, Bagher Farhood, Prostate Cancer and microRNAs: New insights into Apoptosis, 2023, 03440338, 154436, 10.1016/j.prp.2023.154436 | |
| 6. | Lili Zhong, Xiangfu Ding, Xiaoliang Xiong, Tingting Hao, Chao Zhang, Lixing Wang, Yinlong Zhao, The Function and Mechanism of Long Non-Coding RNA RP11-23J9.4 in Thyroid Cancer , 2023, 33, 1045-4403, 53, 10.1615/CritRevEukaryotGeneExpr.2022046595 | |
| 7. | Fazileh Esmaeili, Mohsen Farhadpour, Mahdi Abbas-Mohammadi, Mostafa Alilou, Dina Morshedi, Esmaeil Ebrahimie, Tahmineh Lohrasebi, Appraisals on the anticancer properties of Mentha species using bioassays and docking studies, 2023, 203, 09266690, 117128, 10.1016/j.indcrop.2023.117128 | |
| 8. | Jingdong Li, Zhe Dong, Liting Tang, Lu Liu, Cuijing Su, Shan Yu, Long Non-coding RNA MIR22HG Alleviates Ischemic Acute Kidney Injury by Targeting the miR-134-5p/NFAT5 axis, 2025, 1573-2576, 10.1007/s10753-025-02286-5 | |
| 9. | Marc Thibonnier, Sujoy Ghosh, Review of the Different Outcomes Produced by Genetic Knock Out of the Long Non-coding microRNA-host-gene MIR22HG versus Pharmacologic Antagonism of its Intragenic microRNA product miR-22-3p, 2025, 14, 22115366, 19, 10.2174/0122115366282339240604042154 |
Hao Shen, Xiao-Dong Weng, Du Yang, Lei Wang, Xiu-Heng Liu. Long noncoding RNA MIR22HG is down-regulated in prostate cancer[J]. Mathematical Biosciences and Engineering, 2020, 17(2): 1776-1786. doi: 10.3934/mbe.2020093
DownLoad:
